{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:13:47Z","timestamp":1787739227757,"version":"build-2784847793"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtha.2024.03.021","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T12:30:25Z","timestamp":1712061025000},"page":"2071-2080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy"],"prefix":"10.1016","volume":"22","author":[{"given":"Poorva","family":"Bindal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thita","family":"Chiasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy N.","family":"Lauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amica","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.03.021_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.03.021_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.03.021_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.03.021_bib8","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.03.021_bib10","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/bloodadvances.2020002060","article-title":"Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma","volume":"4","author":"Hashmi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.021_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jth.14759","article-title":"Cytokine and chemokine regulation of venous thromboembolism","volume":"18","author":"Najem","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.021_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.021_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2024.03.021_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.03.021_bib15","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.jtha.2024.03.021_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti\u2013programmed cell death (PD)-1 and anti\u2013programmed death-ligand 1 (PD-L1) blockade in patients with non\u2013small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.021_bib18","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtha.2024.03.021_bib19","doi-asserted-by":"crossref","first-page":"768.e1","DOI":"10.1016\/j.jtct.2021.05.018","article-title":"Outcomes of CD19 chimeric antigen receptor T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma","volume":"27","author":"Cortes-Bullich","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtha.2024.03.021_bib20","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.03.021_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2020.10.005","article-title":"Safety of axicabtagene ciloleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"21","author":"Grana","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtha.2024.03.021_bib22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtha.2024.03.021_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41409-020-01060-5","article-title":"Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy","volume":"56","author":"Hong","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.03.021_bib24","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.021_bib25","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.021_bib26","article-title":"Cardiovascular effects of chimeric antigen receptor t-cell (cart cell) therapy in adults [abstract]","volume":"140","author":"Lefebvre","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.03.021_bib27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/10428194.2022.2030475","article-title":"Incidence of thrombosis in relapsed\/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. Early Access","volume":"63","author":"Melody","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2024.03.021_bib28","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2021-149738","article-title":"Cytopenias in CAR-T cell therapy and use of transfusion resources in adult patients with lymphoproliferative disorders [abstract]","volume":"138","author":"Mezquita","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.03.021_bib30","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jgo.2020.07.006","article-title":"Real-world adverse events associated with CAR T-cell therapy among adults age \u2265 65 years","volume":"12","author":"Zettler","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/10428194.2021.1986216","article-title":"Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2024.03.021_bib34","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T\u00a0cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib35","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T\u00a0cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib36","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B\u00a0cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.03.021_bib37","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A\u00a0phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib39","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41409-021-01226-9","article-title":"CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I\/II clinical trial","volume":"56","author":"Shao","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.03.021_bib40","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A\u00a0phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib41","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.021_bib42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/10428194.2020.1852474","article-title":"Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma","volume":"62","author":"Parks","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2024.03.021_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.2931","article-title":"TNF-\u03b1 increases the risk of bleeding in patients after CAR T-cell therapy: a bleeding model based on a real-world study of Chinese CAR T Working Party","volume":"40","author":"Qi","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib44","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib45","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A\u00a0combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.03.021_bib46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jcyt.2020.01.008","article-title":"Efficacy and toxicity for CD22\/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory aggressive B-cell lymphoma involving the gastrointestinal tract","volume":"22","author":"Zeng","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtha.2024.03.021_bib47","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2021-152465","article-title":"Coagulopathy following chimeric antigen receptor T cell therapy in R\/R adult B cell malignancies: a single center experience [abstract]","volume":"138","author":"Belbachir","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib48","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.03.021_bib49","first-page":"S196","article-title":"Hematopoietic toxicities and coagulopathy following CD22 CAR T-cells [abstract]","volume":"68","author":"Jess","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.03.021_bib50","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib51","article-title":"Cytokine release syndrome is an independent risk factor associated with platelet transfusion refractoriness after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2024.03.021_bib52","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib53","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2021-149181","article-title":"Safety and efficacy of third generation CD20 targeted CAR-T (MB-106) for treatment of relapsed\/refractory B-NHL and CLL [abstract]","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib54","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A\u00a0phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or\u00a0refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.03.021_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564099","article-title":"Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.03.021_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-139007","article-title":"Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-Cell therapy [abstract]","volume":"136","author":"Hong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib59","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.03.021_bib60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(97)10018-6","article-title":"Venous thromboembolism and cancer","volume":"351","author":"Baron","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.03.021_bib61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib62","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.021_bib63","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtha.2024.03.021_bib64","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtha.2024.03.021_bib65","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.021_bib66","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A\u00a0meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:09:37Z","timestamp":1762549777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1538783624001806"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.021","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}